Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $199.19M.
ENTERPRISE VALUE (EV)
$199.19M
Lexeo Therapeutics, Inc. Common Stock
Market Cap
$262.19M
Enterprise Value (EV)
$199.19M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Lexeo Therapeutics, Inc. Common Stock (LXEO) | $262.19M | $199.19M |
| Palisade Bio, Inc. (PALI)vs › | $261.25M | $136.08M |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $264.84M | $233.64M |
| AC Immune S.A. (ACIU)vs › | $259.52M | $230.26M |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $259.46M | $141.59M |
| OraSure Technologies, Inc. (OSUR)vs › | $265.41M | $116.92M |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $265.50M | $215.01M |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $266.20M | $178.11M |
| Anika Therapeutics, Inc. (ANIK)vs › | $258.09M | $242.99M |
| Scribe Therapeutics Inc. (SCTX)vs › | $269.92M | N/A |
Market Cap
$262.19M
Total Debt
$0.00
Cash
$63.00M
Enterprise Value
$199.19M
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
